Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis

Launched by SHEBA MEDICAL CENTER · Mar 21, 2011

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of UC as confirmed by endoscopic or histologic criteria as established by RomeIII
• • Disease activity score of \>5 and ≤13 according to the Simple clinical colitis activity index (SCCAI)
• • Patient on stable 5 ASA medication dose for at least 4 weeks prior to inclusion
• • Patients who receive immunosuppressant or biological therapy (azathioprine, 6-mercaptopurine, infliximab or methotrexate) must be on stable dose for at least 3 months prior to inclusion
• • Patients who receive topical therapy (5ASA or steroidal), must be on stable dose for a least 2 weeks prior to inclusion
• • Patient had hemoglobin of \>10 g/dl.
• • Able and willing to give written consent
• Exclusion Criteria:
• • Patient with renal or liver disease, sever cardiovascular disease, chronic pancreatitis, diabetes mellitus or gallstone.
• • Patient with laboratory abnormalities indicating anemia (hemoglobin \<10), leucopenia, thrombocytopenia, abnormal coagulation.
• • Patient with infection, sepsis or pneumonia.
• • Pregnant or nursing women.
• • Unable or unwilling to receive CURCUMIN therapy.